Rugo, Hope S. http://orcid.org/0000-0001-6710-4814
Kabos, Peter
Beck, J. Thad
Jerusalem, Guy
Wildiers, Hans http://orcid.org/0000-0001-8990-7837
Sevillano, Elena
Paz-Ares, Luis
Chisamore, Michael J.
Chapman, Sonya C. http://orcid.org/0000-0002-6453-2749
Hossain, Anwar M.
Chen, Yanyun
Tolaney, Sara M. http://orcid.org/0000-0002-5940-8671
Funding for this research was provided by:
Eli Lilly and Company
Merck
Article History
Received: 3 March 2022
Accepted: 26 September 2022
First Online: 5 November 2022
Competing interests
: The authors declare no competing nonfinancial interests but the following competing financial interests: H.S.R. reports grants (institutional) from Eli Lilly and Company during the conduct of the study; grants (institutional) from Pfizer, Merck, Novartis, Eli Lilly and Company, Genentech, OBI, Odonate, Daiichi, Eisai, Seattle Genetics, Macrogenics, Sermonixs, Immunomedics and AstraZeneca; educational travel support from Daiichi, Mylan, Pfizer, Merck, Novartis, AstraZeneca, Macrogenics, and honoraria from Puma, Mylan and Samsung outside the submitted work. P.K. reports grants (institutional) from Eli Lilly and Company during the conduct of this study; grants (institutional) from Pfizer, AstraZeneca, Genentech, Radius Health; participated in an advisory board meeting with Eli Lilly and Company. J.T.B. reports grants from Eli Lilly and Company (institutional) during the conduct of the study. G.J. reports personal fees and nonfinancial support from Eli Lilly and Company during the conduct of the study; grants, personal fees and nonfinancial support from Novartis, Roche, and Pfizer; personal fees and nonfinancial support from Lilly, Amgen, BMS and Astra-Zeneca; personal fees from Daiichi-Sankyo and Abbvie; nonfinancial support from Medimmune and MerckKGaA outside the submitted work. H.W. reports grants from Roche; financial support (institutional) for advisory boards and lecture fees from Immutep Pty, MSD, Astrazenca Ireland, Daiichi, AbbVie, Eli Lilly and Company, PSI CRO AG, KCE, EISAI, Astrazeneca, Roche, Lilly, Congres care, Pfizer, ARIEZ, Sirtex, TRM Oncology, ORION Corporation, The Planning Shop, Novartis, Biocartes and Puma Biotech. E.S. reports grants from Roche, MSD and BMS; honoraria from Roche, Janssen, MSD and BMS; travel/meeting expenses Roche and Pfizer; consulting fees from Roche; participation on a data safety monitoring board/advisory board for Roche; leadership/fiduciary role in other board for Roche. L.P.-A. reports fees for scientific advice from MSD, Roche, Eli Lilly and Company, Merck, Novartis, Angem, Takeda, Blueprint, Bayer, Pharmamar, and Pfizer; grants and fees for scientific advice from BMS and Astra Zeneca; and is an external board member for Genomica and a founder and board member for Altum sequencing, outside the submitted work. M.J.C. is an employee and shareholder of Merck & Co., Inc. S.C.C., A.M.H., and Y.C. are employees and shareholders of Eli Lilly and Company. S.M.T. reports research funding from Eli Lilly and Company during the conduct of the study; reports grants (institutional) from AstraZeneca, Eli Lilly and Company, Merck, Nektar, Novartis, Pfizer, Genentech/Roche, Immunomedics/Gilead, Exelixis, BMS, Eisai, Nanostring, Cyclacel, Sanofi, Odonate and SeaGen; honoraria from AstraZeneca, Eli Lilly, Merck, Nektar, Novartis, Pfizer, Genentech/Roche, Immunomedics/Gilead and BMS; consulting fees from Eisai, Nanostring, Sanofi, Odonate, SeaGen, Daiichi-Sankyo, Athenex, OncoPep, Kyowa Kirin Pharma, CytomX, Certara, Mersana Therapeutics, Ellipses Pharma, 4D Pharma, OncoSec, G1 Therapeutics, Silverback Therapeutics, Celldex Therapeutics and OncXerna; participation on a data safety monitoring board<b>/</b>advisory board/steering committee for Odonate, BMS, CytomX, Eli Lilly and Company, Immunomedics, SeaGen, AstraZeneca, Nektar and Gilead/Immunomedics.